Introduction
The age related amyloids have come of age. The increasing attention devoted to Alzheimer's disease in recent years has cast a spotlight on protein, the amyloid fibril protein associated with this disease. However, there is a multitude of other age related amyloids which have been identified. In some instances, the fibril proteins have been identified, whereas, in other cases, the biochemical nature of the amyloids remains unknown (table). Senile systemic amyloid (formerly designated senile cardiac amyloid) is the only clear-cut systemic form of age related amyloid, although the precursor proteins of some localised forms have been identified in the general circulation. In the localised forms the fibril protein precursors are synthesised in the tissue involved by the amyloid.
As a group, the amyloid fibril proteins do not contain a common amino acid sequence essential for the development of the characteristic non-branching fibrils. Of the 17 fibril proteins that have been extracted and sequenced so far, some have been familiar, while others have been novel. One protein, transthyretin (TTR) (prealbumin), has been associated with entirely different forms of amyloidosis in the wild-type and mutated forms. The primary structures ofthese proteins are critical to the formation of amyloid, its sites of deposition and the clinical manifestations, if any. These proteins must accommodate the development of a 1-pleated sheet (antiparallel) configuration, as this arrangement is essential to the formation of the amyloid fibrils and the development oftheir Congophilic staining. The specific events triggering the formation offibrils are unknown. The microenvironment, such as protein concentration, ionic strength, pH, and the presence ofspecific enzymes, proteoglycans and other cellular components, may be critical. The influence of the aging process on this microenvironment and the consequent predisposition to fibril deposition is largely unknown. However, the clinical, pathological and biochemical characteristics of the age related amyloids are becoming better understood.
Senile systemic amyloidosis Senile systemic amyloidosis (SSA) is the most common form of systemic amyloidosis, oc The amyloid fibrils of SSA contain intact TTR together with a family of TTR fragments, the longest of which appears to consist of the -COOH terminal amino acids 46-127. As fragments of consistent length have been found in a number of SSA hearts, it is speculated that these fragments may play a role in the pathogenesis of SSA. Similar fragments are present in amyloid associated with FAP, and in both FAP and SSA, TTR fragments may predominate over the presence of full length TTR molecules. It is not known whether proteolytic cleavage of TTR is a primary and significant event in the fibrillogenesis of 'TTR in either SSA or FAP.
Senile aortic amyloid Aortic amyloid appears to be the most common form of localised amyloid, occurring in nearly all people over 50 years of age. There is growing evidence that there are three distinct forms, involving the media, intima and adventitia. The most common form occurs in the media, where it has been found in 97% of people over 50 years of age. It is much less common in the intima (35% of people over 50 years old). Adventitial amyloid (<5% in the same population) is a manifestation of systemic amyloidosis.
CLINICAL AND PATHOLOGICAL FEATURES
The clinical significance of aortic amyloid is unclear, as there have not been any studies which have shown a causal relation between aortic amyloid and hypertension or dissecting aneurysm.
Medial amyloid is most often located in the inner half of the media and appears as nodules and thin streaks, frequently in proximity to elastin fibres. A number of studies have shown that the thoracic aorta is more commonly involved than the abdominal aorta. Other types of localised amyloid Many other types of age related localised amyloid have been observed, some of which have unique immunological features. Amyloid associated with sclerocalcific heart valves appears to differ from any other cardiovascular amyloid characterised to date.4' Similarly, amyloid associated with porcine bioprosthetic valves does not show immunological cross reactivity with other known amyloid proteins. Small asymptomatic deposits of amyloid are commonly found in articular and periarticular tissues. These deposits are generally localised to cartilage, synovial membrane and fibrous capsule.9 There is evidence that amyloid associated with the hip capsule is frequently of the SSA type. However, age related amyloid associated with other joint structures (knee capsule, hip cartilage and stemoclavicular cartilage) seems to contain a distinctive type of amyloid.9
Conclusion
The age related amyloids represent an extremely varied group of pathological entities. Some forms of amyloid, such as aortic and choroid plexus, are present in virtually all elderly people. On the basis of currently available information, all major forms of senile amyloidosis seem to be derived from normally synthesised proteins. TTR seems to have the most distinctive characteristics of all the amyloid fibril proteins of producing a generally benign amyloidosis in its native form (SSA) and a malignant, lethal amyloidosis in its mutant form (FAP).
Many ofthe localised age related amyloids do not appear to cause clinical disease. However, although the complex mechanisms are not completely understood, the f protein and IAPP derived amyloids are generally considered to have significant links to their respective associated clinical diseases (Alzheimer's disease and type 2 diabetes mellitus). Although the precursor protein of the intimal type of senile aortic amyloid is unknown, its relation to atherosclerosis deserves further study. Irrespective of how the debate regarding the pathological significance ofthe age related amyloids evolves, further characterisation of their fibril protein structures promises to advance our understanding of the entire complex and puzzling family of amyloidoses.
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